Prognostic Value of Hepatocyte Growth Factor for Muscle-invasive Bladder Cancer
release_ff5fojq5l5cezicp5tg5kygc5e
by
Satoshi Katayama,
Victor M. Schuettfort,
Benjamin Pradere,
Keiichiro Mori,
Hadi Mostafaei,
Fahad Quhal,
Reza Sari Motlagh,
Ekaterina Laukhtina,
Nico C. Grossmann,
Abdulmajeed Aydh,
Pawel Rajwa,
Frederik König
(+11 others)
2021
Abstract
<jats:title>Abstract</jats:title>
PurposeThe HGF/MET pathway is involved in cell motility, angiogenesis, proliferation, and cancer invasion. We assessed the clinical utility of plasma HGF level as a prognostic biomarker in patients with MIBC.MethodsWe retrospectively analyzed 565 patients with MIBC who underwent radical cystectomy. Logistic regression and Cox regression models were used, and predictive accuracies were estimated using the area under the curve and concordance index. To estimate the clinical utility of HGF, DCA and MCID were applied.ResultsPlasma HGF level was significantly higher in patients with advanced pathologic stage and LN metastasis (<jats:italic>p</jats:italic>=0.01 and <jats:italic>p</jats:italic><0.001, respectively). Higher HGF levels were associated with an increased risk of harboring LN metastasis and non-organ-confined disease (OR1.21, 95%CI 1.12-1.32, <jats:italic>p</jats:italic><0.001, and OR1.35, 95%CI 1.23-1.48, <jats:italic>p</jats:italic><0.001, respectively) on multivariable analyses; the addition of HGF improved the predictive accuracies of a standard preoperative model (+7%, <jats:italic>p</jats:italic><0.001 and +8%, <jats:italic>p</jats:italic><0.001, respectively). According to the DCA and MCID, half of the patients had a net benefit by including HGF, but the absolute magnitude remained limited. In pre- and postoperative predictive models, a higher HGF level was significant prognosticator of worse RFS, OS, and CSS; in the preoperative model, the addition of HGF improved accuracies by 6% and 5% for RFS and CSS, respectively.ConclusionPreoperative HGF identified MIBC patients who harbored features of clinically and biologically aggressive disease. Plasma HGF could serve, as part of a panel, as a biomarker to aid in preoperative treatment planning regarding intensity of treatment in patients with clinically MIBC.
In application/xml+jats
format
Archived Files and Locations
application/pdf
511.2 kB
file_d6o6ccl4qfb3zpz3x57qkdj72u
|
assets.researchsquare.com (publisher) web.archive.org (webarchive) |
post
Stage
unknown
Date 2021-09-27
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar